Skip to content

Clinical Study for Evaluating the Clinical Safety and Effectiveness of the Automated Robotic Robot, Revo-i Surgical Robot System (Model MSR-5100), Used for General Endoscopic Surgery.

A Prospective, Single-center, Single-group Clinical Study for Evaluating the Clinical Safety and Effectiveness of the Automated Robotic Robot, Revo-i Surgical Robot System (Model MSR-5100), Used for General Endoscopic Surgery.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04095312
Enrollment
33
Registered
2019-09-19
Start date
2019-09-17
Completion date
2020-04-30
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periampullary Cancer

Brief summary

This study is based on the ergonomic features of the most common surgical procedures, which require advanced techniques and relatively difficult operations, such as pancreatobiliary surgery, prostatectomy, nephrectomy, colon and rectal resection. This study id designed to verify the clinical safety and effectiveness of 'Revo-i Surgical Robot System (Model MSR-5100), developed by Mirae Company to overcome the limitations of general laparoscopic surgery.

Interventions

PROCEDURERevo-i robotic surgery system (Model MSR-5100)

for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

In a study involving relatively small groups of 10 to 50 people, the study showed a high success rate of more than 90% similar to the study of more than 100 large groups, and the stability was well proven. total 33 patients (10 pancreaticobiliary tracts, 13 urinary tract areas, 10 colonic areas), the minimum number of clinical studies that can be statistically analyzed within the limits to meet the study objective of evaluating the accuracy of procedure

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

All of the following selection criteria must be met to be enrolled in this clinical trial. * Common Standard 1. Adults over 19 2. Voluntary consent to clinical research and willingness to comply with the protocol * Pancreaticobiliary tract area surgery 1. A person deemed to need surgery for pancreaticobiliary tract due to one or more of the following reasons: * Benign and borderline periampullary cancer * Resectable masses (biliary cancer, pancreatic cancer, duodenal cancer, AoV cancer, etc.) Congenital gallbladder cysts * Endoscopic treatment of adenocarcinoma and early stage lesions of ampulla * There is no major organ or vascular invasion * Lack of severe pancreatitis and cholangitis 2. Patients considering laparoscopic surgery who cannot perform da Vinci robot surgery due to personal expense 3. Others who have been diagnosed with high latitude pancreaticobiliary tract surgery according to the researcher's judgment * Prostatectomy 1. Persons deemed necessary for prostatectomy in the following cases: -The prostate is at low risk or medium risk, and the tumor is located at the local site without metastasis Criteria for Prostate Risk Group Prostate low risk group Prostate Cancer Stage (T1-T2a) and Gleason Grade ≤6 and PSA \<10ng / ml Risk group in the prostate Prostate cancer stage (T2b-T2c) or Gleason grade 7 or10 ng / ml ≤ PSA ≤ 20 ng / ml \* Reference) NCCN (National Comprehensive Cancer Network), 2015 2. Others who have been diagnosed as requiring prostate surgery according to the researcher's judgment * Nephrectomy 1. Persons deemed necessary for renal resection should: Localized renal cell carcinoma without metastasis to organs other than the kidney Stage 1A, IB, II, III \* Reference) NCCN (National Comprehensive Cancer Network), 2011 2. Others who have been diagnosed with nephrectomy according to the researcher's judgment * Colon and Rectal Surgery 1. A person who needs to have a resection for colon and rectal cancer * Histopathologically confirmed by adenocarcinoma of the rectum or colon * No remote transition (M0) * Primary tumor without other peripheral organ involvement (T1-T4a) * When intestinal obstruction is not accompanied In case of elective surgery * Does not require resection of any organ other than the primary tumor 2. Others who have been diagnosed as having to need colon and rectal resection according to the researcher's judgment

Exclusion criteria

* Common Standard 1. If you have mental illness or serious systemic disease 2. Body Mass Index (BMI) ≥ 30, high obesity 3. General anesthesia is not possible due to uncontrolled bleeding tendency or lowering of cardiopulmonary function 4. If you have a positive or reactive pregnancy 5. Patients who wish to undergo conventional laparoscopy or da Vinci robotic surgery * Pancreaticobiliary tract area surgery -If you have a history of open abdominal surgery Liver cirrhosis Patients with abnormally inoperable pancreatobiliary malformations, other pancreatic biliary diseases, or systemic diseases * Prostatectomy 1. Surgical removal of prostate tumor is difficult or life expectancy is short 2. Meets the

Design outcomes

Primary

MeasureTime frameDescription
Operation success rate24hours after operationSurgery is complete without significant complications up to 24 hours after surgery and without conversion to other operations (laparotomy or laparoscopy)

Secondary

MeasureTime frameDescription
Operative outcomeimmediate postoperationOperation time (minute)

Countries

South Korea

Contacts

Primary ContactChang Moo Kang
CMKANG@yuhs.ac82-2-2228-2135

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026